Table 2 Laboratory profile, imaging, and histopathology of patients with ILD and a positive anti-Ro52 antibody
From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody
Variable | All patients n = 73 | Stratified by Autoantibodies | |||
|---|---|---|---|---|---|
Isolated Anti-Ro52 n = 50 | Anti-Ro52 plus myositis-specific autoAb n = 23 | Raw p-value | Adjusted p-value* | ||
Anti-Ro52 titer (nl < 20 Units), median [interquartile range] | 59 [31–122] | 44.5 [28–98] | 108 [41–140] | 0.01 | 0.25 |
ANA, n (%) | 0.07 | 0.85 | |||
Negative | 13 (17.8%) | 9 (18%) | 4 (17.4%) | ||
Positive titer <1:320 | 31 (42.5%) | 17 (34%) | 14 (60.9%) | ||
Positive titer > = 1:320 | 29 (39.7%) | 24 (48%) | 5 (21.7%) | ||
Creatine kinase (nl < 400 U/L), median [range] | 110 [13–13,965] (n = 63) | 102 [13–13,965] (n = 42) | 119 [21–1774] (n = 21) | 0.73 | 1.0 |
Aldolase (nl < 7.7 U/L), median [range] | 7.90 [3.8–273] (n = 67) | 8.0 [3.9–273] (n = 45) | 7.15 [3.8–45] (n = 22) | 0.25 | 1.0 |
SS-A ELISA positive, n (%) | 9 (14.3%) (n = 63) | 8 (18.2%) (n = 44) | 1 (5.3%) (n = 19) | 0.26 | 1.0 |
Positive cytoplasmic Ab, n (%) | 17 (23.3%) | 5 (10%) | 12 (52.2%) | <0.0001 | 0.002 |
Dominant radiographic pattern, n (%) | 0.93 | 1.0 | |||
OP | 25 (34.3%) | 16 (32%) | 9 (39.1%) | ||
NSIP | 14 (19.2%) | 10 (20%) | 4 (17.4%) | ||
UIP | 13 (17.8%) | 8 (16%) | 5 (21.7%) | ||
Mixed OP/NSIP | 10 (13.7%) | 8 (16%) | 2 (8.7%) | ||
HP | 4 (5.5%) | 3 (6%) | 1 (4.4%) | ||
Sarcoid | 2 (2.7%) | 1 (2%) | 1 (4.4%) | ||
LIP | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
DAD | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
PPFE | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
Infection/aspiration | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
Other | 1 (1.4%) | 0 (0%) | 1 (4.4%) | ||
Fibrosis present, n (%) | 37 (50.7%) | 25 (50%) | 12 (52.2%) | 0.86 | 1.0 |
Lung biopsy pathology, n (%) | 0.07 | 0.85 | |||
OP | 7 (9.6%) | 5 (10%) | 2 (8.7%) | ||
NSIP | 3 (4.1%) | 3 (6%) | 0 (0%) | ||
UIP | 1 (1.4%) | 0 (0%) | 1 (4.4%) | ||
Mixed OP/NSIP | 3 (4.1%) | 0 (0%) | 3 (13%) | ||
HP | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
Sarcoid | 1 (1.4%) | 1 (2%) | 0 (0%) | ||
No biopsy | 57 (78.1%) | 40 (80%) | 17 (73.9%) | ||